Mesoblast Limited
AUFinancials
Valuation Metrics
Mesoblast Limited's Market Cap is $1.88B. At end of 2025 it was $2.30B. Ranked #1979 of 3,118 in US market (top 63%), #740 of 1,474 on NASDAQ (top 50%), #136 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.88B | US#1,979/3,118 Sec#136/265 |
| Revenue | $120M | US#2,639/3,118 Sec#119/265 |
| Net Income | $-58M | US—/3,118 Sec—/265 |
| Total Assets | $773M | US#2,576/3,118 Sec#122/265 |
| Net Assets | $568M | US#2,136/3,118 Sec#98/265 |
| Employees | 81 | US#2,648/3,118 Sec#188/265 |
| Value | ||
| P/B | 3.31x | US#1,918/3,118 Sec#108/265 |
| P/S | 15.63x | US#2,820/3,118 Sec#136/265 |
| FCF Yield | -2.25% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -10.12% | US#2,364/3,118 Sec#80/265 |
| ROA | -7.44% | US#2,597/3,118 Sec#94/265 |
| Op. Margin | -42.83% | US#2,639/3,118 Sec#108/265 |
| Revenue Growth | 599.21% | US#24/3,118 Sec#14/265 |
| Financial Health | ||
| Debt Ratio | 36.01% | US#407/3,118 Sec#118/265 |
| Total Debt | $127M | US#2,364/3,118 Sec#108/265 |
| FCF | $-42M | US#2,497/3,118 Sec#109/265 |
| Cash | $103M | US#2,213/3,118 Sec#172/265 |
| Current Ratio | 2.43x | US#998/3,118 Sec#203/265 |
| Performance | ||
| 1Y Return | -12.73% | US#2,062/3,118 Sec#163/265 |
| 1M Return | 3.27% | US#1,402/3,118 Sec#79/265 |
| From 52W High | -32.37% | US#1,921/3,118 Sec#119/265 |
| 1Y MDD | -42.99% | US#2,079/3,118 Sec#136/265 |
| Trading | ||
| Volume | 261,018 shares | US#2,308/3,118 Sec#219/265 |
| Trading Value | $4M | US#2,587/3,118 Sec#205/265 |
| Per Share | ||
| EPS | $-0.44 | US—/3,118 Sec—/265 |
| BPS | $4.40 | US#2,318/3,118 Sec#133/265 |
Company Info
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.